局部晚期非小细胞肺癌患者不同新辅助治疗方案中TAMs的水平变化和疗效相关性分析  

The correlation analysis of TAMs in different neoadjuvant regimens in locally advanced non-small cell lung cancer

作　　者：李索妮 呼延卓雅 马婕群 廖子君 张彦兵 LI Suoni;HUYAN Zhuoya;MA Jiequn;LIAO Zijun;ZHANG Yanbing(Department of Oncology,Shaanxi Provincial Tumor Hospital,Shaanxi Xi'an 710061,China;Rheumatology and Immunology Department,Xi'an No.3 Hospital,Shaanxi Xi'an 710021,China.)

机构地区：[1]陕西省肿瘤医院内一科,陕西西安710061 [2]西安市第三医院风湿免疫科,陕西西安710021

出　　处：《现代肿瘤医学》2024年第19期3694-3699,共6页Journal of Modern Oncology

基　　金：陕西省重点研发计划基金资助项目(编号:2022SF282)。

摘　　要：目的:分析局部晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者不同新辅助治疗方案中肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)的水平变化和疗效相关性。方法:收集我院2018年01月01日至2022年06月30日接受新辅助治疗及手术治疗的患者163例,按照新辅助治疗方案不同分为新辅助免疫联合化疗组及新辅助化疗组,进行MPR计算,并对影响MPR的因素进行分析;同时对其中具有治疗前后配对标本的37例患者进行TAMs相关分子(CD68、CD86、CD163)的免疫组化染色,分析治疗前后指标变化与临床疗效间的相关性。结果:新辅助免疫联合化疗组MPR明显高于新辅助化疗组(58.6%vs 21.3%,P<0.001)。新辅助免疫联合化疗组中,治疗后CD86的阳性表达率高于治疗前(75%vs 16.7%,P=0.039);CD163、CD68的表达水平在治疗前后无明显差异(P>0.05)。新辅助化疗组中,治疗后CD68、CD86的阳性表达率均高于治疗前(64%vs 28%,P=0.035)、(68%vs 28%,P=0.021);CD163的表达水平在治疗前后差异无明显差异(P>0.05)。CD68、CD86、CD163的表达在新辅助免疫联合化疗及化疗组组间比较差异无统计学意义(P>0.05)。新辅助免疫联合化疗组中,CD86治疗前后表达的变化与MPR呈正相关(r s=0.577,P=0.046);但CD68与CD163治疗前后表达的变化与MPR之间无显著相关性(P>0.05)。新辅助化疗组中,CD68、CD163、CD86治疗前后表达的变化与MPR之间均无显著相关性(P>0.05)。结论:可切除局部晚期NSCLC患者新辅助免疫联合化疗相比于新辅助化疗能够为患者带来更高的MPR率;M1型(CD86)TAMs的变化可作为新辅助免疫联合化疗疗效预测的潜在生物标志物。Objective:Analysis of tumor-associated macrophages(TAMs)levels and efficacy correlation in different neoadjuvant regimens in locally advanced non-small cell lung cancer(NSCLC).Methods:Collect 163 patients who received neoadjuvant therapy and surgical treatment at our hospital from January 1,2018 to June 30,2022.Divide them into two groups according to different neoadjuvant treatment regimens:Neoadjuvant immunotherapy combined with chemotherapy group and neoadjuvant chemotherapy group,and perform MPR calculation.And analyze the factors which affect MPR.At the same time,immunohistochemical staining of TAMs related molecules(CD68,CD86,CD163)was performed on 37 patients with pre-and post treatment paired specimens to analyze their correlation with clinical efficacy.Results:The MPR of the neoadjuvant immunotherapy combined with chemotherapy group was significantly higher than that of the neoadjuvant chemotherapy group(58.6%vs 21.3%,P<0.001).In the neoadjuvant immunotherapy combined with chemotherapy group,the positive expression rate of CD86 after treatment was higher than before treatment(75%vs 16.7%,P=0.039).There was no significant difference in the expression levels of CD163 and CD68 before and after treatment(P>0.05).In the neoadjuvant chemotherapy group,the positive expression rates of CD68 and CD86 after treatment were higher than before treatment(64%vs 28%,P=0.035)and(68%vs 28%,P=0.021).But the expression level of CD163 showed no significant difference before and after treatment(P>0.05).There was no statistically significant difference in the expression of CD68,CD86,and CD163 between the neoadjuvant immunotherapy combined with chemotherapy and chemotherapy groups(P>0.05).In addition,in the neoadjuvant immunotherapy combined with chemotherapy group,the changes in CD86 expression before and after treatment were positively correlated with MPR(r s=0.577,P=0.046).However,there was no significant correlation between the expression changes of CD68 and CD163 before and after treatment and MPR(P>0.05).In the neoadjuvan

关 键 词：非小细胞肺癌 新辅助免疫联合治疗 主要病理缓解 肿瘤相关巨噬细胞 

分 类 号：R734.2[医药卫生—肿瘤]